NASDAQ:FBLG FibroBiologics Q2 2026 Earnings Results & Report $0.84 -0.06 (-6.72%) Closing price 04:00 PM EasternExtended Trading$0.83 -0.01 (-1.19%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. FibroBiologics beat analyst earnings expectations in its Q2 2026 results, released July 31, 2026. The company reported EPS of -$0.66 versus the -$0.93 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateJuly 31, 2026TimeBefore Market OpensConference Call7:00 AM ET FibroBiologics EPS ResultsActual EPS-$0.66Consensus EPS -$0.93Beat/MissBeat by +$0.27One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersFibroBiologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsFibroBiologics' Q4 2026 earnings is estimated for Friday, November 20, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) FibroBiologics Q2 2026 Earnings FAQ Did FibroBiologics beat earnings estimates for Q2 2026? FibroBiologics (NASDAQ:FBLG) reported earnings of -$0.66 per share for Q2 2026, beating the consensus estimate of -$0.93. The report was announced on Friday, July 31, 2026. When is FibroBiologics' next earnings date? FibroBiologics' next earnings date is estimated for Friday, November 20, 2026. MarketBeat tracks confirmed and estimated earnings dates for FibroBiologics on the company's earnings history page. FibroBiologics Earnings HeadlinesFibroBiologics Inc. (NASDAQ:FBLG) Stock Rated "Reduce" by Wall Street AnalystsNovember 17 at 7:44 AM | americanbankingnews.comFibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming CatalystsNovember 16 at 4:13 PM | prnewswire.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.November 18 at 1:00 AM | Paradigm Press (Ad)Join FibroBiologics’ Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value IndicationsNovember 12, 2026 | usatoday.comFibroBiologics Announces Update On Its Intellectual Property PortfolioNovember 12, 2026 | prnewswire.comFibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory AgentsNovember 5, 2026 | prnewswire.comSee More FibroBiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email. Email Address About FibroBiologicsFibroBiologics (NASDAQ:FBLG) is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes. The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments. FibroBiologics is based in Houston, Texas. The company was founded by Pete O’Heeron, who serves as its chief executive officer.View FibroBiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.